Renaissance Capital logo

Kronos Bio Priced, Nasdaq: KRON

Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors.

Industry: Health Care

Latest Trade: $3.82 +0.18 (+4.8%)

First Day Return: +42.5%

Return from IPO: -80.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Our lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that has been tested in 148 acute myeloid leukemia (AML) patients. Based on clinical results in a biomarker-defined subset of patients and subject to discussions with regulatory agencies that we intend to have in the first half of 2021, we plan to initiate a registrational Phase 2/3 clinical trial in 2021 in newly-diagnosed AML patients with NPM1 mutations, with an anticipated data readout in 2023. We are also planning to initiate a Phase 1/2 clinical trial in patients with relapsed or refractory FLT3 mutated AML in 2021. In addition, we are developing KB-0742, which is designed to be an orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) with a differentiated selectivity profile, for the treatment of MYC-amplified solid tumors. Subject to clearance of an Investigational New Drug application (IND) for KB-0742, which we plan to submit in the fourth quarter of 2020, we plan to initiate a Phase 1/2 clinical trial in patients with advanced solid tumors in 2021. In addition, we are leveraging our product engine to drive multiple oncology discovery programs targeting dysregulated transcription factors and their associated TRNs.
more less
IPO News for Kronos Bio
more
IPO Data
IPO File Date 09/18/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 13.2
Deal Size ($mm) $250
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/08/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 13.2
Deal Size ($mm) $250
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Mateo, CA
Founded 2017
Employees 45
Website www.kronosbio.com